Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Atogepant
Drug ID BADD_D02529
Description Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.[L38814] While its approval was predated by two other members of the same drug family, namely [ubrogepant] and [rimegepant], these agents are indicated only for abortive migraine therapy - atogepant is novel in that it is the first and only oral CGRP antagonist approved for preventative use in migraine.[L38814] In patients requiring preventative migraine therapy, current practice guidelines recommend the use of certain anti-epileptic medications (e.g. [valproic acid] or [topiramate]) or beta-blockers (e.g. [propranolol]), all of which can be associated with significant adverse effects.[A239094] The "gepants" family of drugs, including atogepant, are comparatively well-tolerated[A189207,L38739] and may provide a desirable treatment option for patients struggling with adverse reactions to other preventative therapies.
Indications and Usage Atogepant is indicated for the prevention of episodic migraine in adults.[L38739]
Marketing Status approved; investigational
ATC Code N02CD07
DrugBank ID DB16098
KEGG ID D11313
MeSH ID C000718987
PubChem ID 72163100
TTD Drug ID D02ZUG
NDC Product Code 0074-7093; 0074-7092; 0074-7091; 0074-7096; 0074-7094; 0074-7095
UNII 7CRV8RR151
Synonyms atogepant | (3S)-N-((3S,5S,6R)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl)-2-oxospiro(1H-pyrrolo(2,3-b)pyridine-3,6'-5,7-dihydrocyclopenta(b)pyridine)-3'-carboxamide
Chemical Information
Molecular Formula C29H23F6N5O3
CAS Registry Number 1374248-81-3
SMILES CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC (=C6F)F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.000340%-
Abdominal pain upper07.01.05.0030.000566%
Alopecia23.02.02.0010.000340%
Anxiety19.06.02.0020.000340%
Cerebrovascular accident17.08.01.007; 24.03.05.0010.000067%
Confusional state17.02.03.005; 19.13.01.0010.000067%
Constipation07.02.02.0010.004402%
Depression19.15.01.0010.000260%
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.001425%
Drug ineffective08.06.01.0060.002524%-
Dry mouth07.06.01.0020.000226%
Dyspepsia07.01.02.0010.000260%
Fatigue08.01.01.0020.001359%
Feeling abnormal08.01.09.0140.000340%-
Feeling jittery08.01.09.0160.000226%-
Gastrointestinal disorder07.11.01.0010.000566%-
Hallucination19.10.04.0030.000147%
Headache17.14.01.0010.001312%
Hypersensitivity10.01.03.0030.000340%
Hypertension24.08.02.0010.000147%
Insomnia17.15.03.002; 19.02.01.0020.000453%
Irritable bowel syndrome07.02.04.003; 19.24.01.0030.000260%-
Memory impairment17.03.02.003; 19.20.01.0030.000067%
Migraine17.14.02.001; 24.03.05.0030.001945%-
Muscle twitching15.05.03.0050.000147%-
Myalgia15.05.02.0010.000226%
Nausea07.01.07.0010.005274%
Palpitations02.11.04.0120.000453%
Photophobia06.01.01.004; 17.17.02.0060.000226%
Pregnancy18.08.02.0040.000226%-
The 1th Page    1 2    Next   Last    Total 2 Pages